Literature DB >> 29161163

Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011.

Raquel Marçôa1, Daniela Marta Rodrigues2, Margarida Dias1, Inês Ladeira1, Ana Paula Vaz2, Ricardo Lima1, Miguel Guimarães1.   

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality worldwide. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) project has been working to improve awareness, prevention and management of this disease. The aim of this study is to evaluate how COPD patients are reclassified by the 2017 GOLD system (versus GOLD 2011), to calculate the level of agreement between these two classifications in allocation to categories and to compare the performance of each classification to predict future exacerbations. Two-hundred COPD patients (>40 years, post bronchodilator forced expiratory volume in one second/forced vital capacity<0.7) followed in pulmonology consultation were recruited into this prospective multicentric study. Approximately half of the patients classified as GOLD D [2011] changed to GOLD B [2017]. The extent of agreement between GOLD 2011 and GOLD 2017 was moderate (Cohen's Kappa = 0.511; p < 0.001) and the ability to predict exacerbations was similar (69.7% and 67.6%, respectively). GOLD B [2017] exacerbated 17% more than GOLD B [2011] and had a lower percent predicted post bronchodilator forced expiratory volume in one second (FEV1). GOLD B [2017] turned to be the predominant category, more heterogeneous and with a higher risk of exacerbation versus GOLD B [2011]. Physicians should be cautious in assessing the GOLD B [2017] patients. The assessment of patients should always be personalized. More studies are needed to evaluate the impact of the 2017 reclassification in predicting outcomes such as future exacerbations and mortality.

Entities:  

Keywords:  COPD; Global Initiative for Chronic Obstructive Lung Disease; assessment; exacerbation; stratification

Mesh:

Year:  2017        PMID: 29161163     DOI: 10.1080/15412555.2017.1394285

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  23 in total

1.  The London Chest Activity of Daily Living scale cut-off point to discriminate functional status in patients with chronic obstructive pulmonary disease.

Authors:  Aline Almeida Gulart; Anelise Bauer Munari; Suelen Roberta Klein; Raysa Silva Venâncio; Hellen Fontão Alexandre; Anamaria Fleig Mayer
Journal:  Braz J Phys Ther       Date:  2019-03-26       Impact factor: 3.377

2.  Performance difference on the six-minute walk test on tracks of 20 and 30 meters for patients with chronic obstructive pulmonary disease: validity and reliability.

Authors:  Suelen Roberta Klein; Aline Almeida Gulart; Raysa Silva Venâncio; Anelise Bauer Munari; Simone Graciosa Gavenda; Ana Carolina Benedet Martins; Anamaria Fleig Mayer
Journal:  Braz J Phys Ther       Date:  2020-01-22       Impact factor: 3.377

3.  Clinical efficacy of glucocorticoid and terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Yan Li; Zhi Xu; Cuo Qing; Hong Zhang; Xia Wu; Jilu Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

4.  Comparative Study of Cytokine Levels in Different Respiratory Samples in Mild-to-Moderate AECOPD Patients.

Authors:  Wendong Hao; Manxiang Li; Yunqing Zhang; Cailian Zhang; Ping Wang
Journal:  Lung       Date:  2019-08-26       Impact factor: 2.584

5.  Classification and treatment of chronic obstructive pulmonary disease outpatients in China according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: comparison with GOLD 2014.

Authors:  Yanan Cui; Zhongshang Dai; Lijuan Luo; Ping Chen; Yan Chen
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

6.  Pulmonary Dysfunction Augmenting Bacterial Aerosols in Leather Tanneries of Punjab, Pakistan.

Authors:  Fiza Sarwar; Khan Alam; Chung Wai Chow; Muhammad Saeed; Riffat Naseem Malik
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-10-27

Review 7.  Pulmonary function testing in COPD: looking beyond the curtain of FEV1.

Authors:  Sotirios Kakavas; Ourania S Kotsiou; Fotis Perlikos; Maria Mermiri; Georgios Mavrovounis; Konstantinos Gourgoulianis; Ioannis Pantazopoulos
Journal:  NPJ Prim Care Respir Med       Date:  2021-05-07       Impact factor: 2.871

Review 8.  Role of Nuclear Factor Erythroid 2‒Related Factor 2 in Chronic Obstructive Pulmonary Disease.

Authors:  Woo Ho Ban; Chin Kook Rhee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-03-08

9.  Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD.

Authors:  Antonello Nicolini; Bruna Grecchi; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-16

10.  Causal Effects of Body Mass Index on Airflow Obstruction and Forced Mid-Expiratory Flow: A Mendelian Randomization Study Taking Interactions and Age-Specific Instruments Into Consideration Toward a Life Course Perspective.

Authors:  Nicole Probst-Hensch; Ayoung Jeong; Daiana Stolz; Marco Pons; Paola M Soccal; Robert Bettschart; Deborah Jarvis; John W Holloway; Florian Kronenberg; Medea Imboden; Christian Schindler; Gianfranco F Lovison
Journal:  Front Public Health       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.